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Objectives. This study was performed to examine the effect of 
dobutamine stress echocardiography on mitral regurgitation and 
to test the hypothesis that mitral regurgitation will increase in 
patients with an ischemic response. 
Background. New or worsening mitral regurgitation during 
stress testing has been proposed as a marker of ischemia. 
However, it is unclear whether ischemia induced by dobutamine is 
associated with mitral regurgitation because the hemodynamic 
effects of dobutamine may vary with regard to mitral regurgita- 
tion, depending on left ventricular function and maximal dose 
attained. 
Methods. Dobutamine stress echocardiography was performed 
in 102 consecutive patients with suspected or known coronary 
artery disease. Color flow Doppler was used to determine the 
presence and change in mitral regurgitation atbaseline and peak 
dobutamine infusion (up to 40 pg/kg body weight per rain). The 
mitral regurgitation color flow Doppler area was semiquantita- 
tively graded as mild (<4 cm2), moderate (4 to 8 cm 2) or severe 
(>8 cm2). Patients were assigned to ischemic and nonischemic 
groups according to the dobutamine stress echocardiographic 
results. 
Results. The two groups achieved the same maximal dose and 
demonstrated similar blood pressure and heart rate responses to 
dobutamine infusion. Only two patients developed new mitral 
regurgitation during dobutamine infusion, and both had a normal 
dobutamine echocardiographic result. More patients without isch- 
emia had no mitral regurgitation compared with patients with 
ischemia. There was an insufficient number of patients with 
coronary angiographic data to determine the effects of mitral 
regurgitation on the sensitivity and specificity of dobutamine 
stress echocardiography. Of 23 patients with a rest ejection 
fraction <50%, 61% had an improvement in mitral regurgitation 
grade compared with 25% of patients with a rest ejection fraction 
>50% (p < 0.02). 
Conclusions. These data indicate that although dobutamine 
infusion often improves mitral regurgitation i patients with left 
ventricular dysfunction during stress echocardiography, it does 
not induce or worsen mitral regurgitation i those who demon- 
strate an ischemic response. Future studies are necessary, with 
larger numbers of patients, to determine the effects of mitral 
regurgitation on the sensitivity and specificity of dobutamine 
stress echocardiography. 
(J Am Coll Cardiol 1995;25:122-7) 
Dobutamine stress echocardiography as emerged as an im- 
portant alternative method for evaluating patients with coro- 
nary artery disease (1-4). A potential advantage of this 
technique over nuclear imaging methods is the ability to 
simultaneously assess mitral regurgitation by color flow Dopp- 
ler. It has been suggested that the development of new mitral 
regurgitation improves the sensitivity of dobutamine stress 
echocardiography for detecting coronary artery disease (3). 
Dobutamine has beneficial hemodynamic effects, particularly in 
the failing heart (5-7) and in patients with chronic mitral regur- 
gitation (8,9). However, the effect of stress doses of dobutamine 
on mitral regurgitation is unclear. It is also not currently known 
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how the beneficial hemodynamic effects interact with dobu- 
tamine-induced ischemia to affect mitral regurgitation. 
This study was performed to examine the effect of dobut- 
amine stress echocardiography on mitral regurgitation and to 
test the hypothesis that mitral regurgitation will increase in 
patients with an ischemic response during dobutamine stress 
echocardiography. 
Methods  
Patients. The study included 102 consecutive patients (44 
men, 58 women; mean [_+SD] age 62 _+ 14 years, range 29 to 
94) who were referred for dobutamine stress echocardiography 
to evaluate known or suspected coronary artery disease. Pa- 
tients with unstable angina, advanced symptoms of congestive 
heart failure, uncontrolled hypertension, hypertrophic ear- 
diomyopathy, critical aortic stenosis or a history of sustained 
ventricular arrhythmia were excluded. The indications for 
dobutamine stress echocardiography included chest pain in 
61%, preoperative risk assessment in 13%, functional signifi- 
cance of known coronary lesions in 9%, myocardial infarction 
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in 4%, revascularization in 2% and other miscellaneous rea- 
sons in 11%. No cardiac medications were withheld before the 
study. Beta-adrenergic blocking agents were taken by 31% of 
patients, calcium channel blocking agents by 39% and nitrates 
by 55%. 
Dobutamine stress echocardiography. Baseline hemo- 
dynamic, electrocardiographic (ECG) and echocardiographic 
data were recorded. Dobutamine was then infused intravenously 
in an incremental regimen of 5, 10, 20, 30 and 40 txg/kg body 
weight per rain for 3 rain at each dose. End points of the infusion 
included achievement of 85% of age-predicted maximal heart 
rate, diagnostic ST segment depression, ew wall motion abnor- 
mality, significant symptoms or arrhythmia, severe hypertension 
(systolic blood pressure >200 mm Hg or diastolic blood pressure 
>110 mm Hg), severe hypotensive r sponse (decrease in blood 
pressure from baseline >20 man Hg) or completion of the 
protocol. If the target heart rate was not achieved, atropine was 
administered intravenously in incremental doses to a maximal 
total dose of 2 mg. Intravenous lopressor and esmolol were 
available to treat persistent adverse ffects. A 12-lead ECG was 
obtained at every 3-rain stage. Heart rate and blood pressure were 
recorded every 1 to 2 rain by automated cuff monitor. 
Two dimensional echocardiography (Hewlett-Packard 77020, 
Interspec Apogee CX 200) was performed in the parasternal 
long-axis, short-axis and apical four- and two-chamber views at 
baseline, 2rain into low dose (10 txg/kg) and peak dose and at 
least 5 min after the dobutamine infusion was terminated. 
Mitral regurgitation was evaluated by color flow Doppler 
imaging (2.5-MHz transducer) in the parasternal long-axis and 
apical views at baseline and at peak dose. The gain settings 
were standardized initially by increasing the setting until color 
signals were seen outside the flow area and then reduced until 
these extraneous signals disappeared. The optimized gain 
settings and depth were maintained for each patient hrough- 
out the study. The color map was set to optimize the color 
variance signal. Semiquantitative analysis of mitral regurgita- 
tion was performed by two independent observers and was 
based on the total regurgitant jet area and graded as mild 
(<4 cm2), moderate (4 to 8 cm 2) and severe (>8 cruZ), as 
previously described (10). A significant change in mitral regur- 
gitation was defined as a change of at least one grade com- 
pared with baseline. 
Stress echocardiographic analysis was performed from a 
digital quad screen display (Nova Microsonics Image Vue) by 
two independent experienced observers who had no knowl- 
edge of the clinical and angiographic data. The left ventricle 
was divided into 16 segments according to American Society of 
Echocardiography criteria (11). Results of the dobutamine 
stress echocardiogram were considered normal if all segments 
that were normal at baseline showed a hyperdynamic response 
with increased systolic wall thickening. The development of
new or worsening regional asynergy, defined as hypokinesia, 
akinesia or dyskinesia during dobutamine stress, was consid- 
ered consistent with ischemia. The persistence of baseline 
asynergy, without worsening, was considered to be consistent 
with infarction without inducible ischemia. 
Table l. Hemodynamic Response During Dobutamine 
Stress Echocardiography 
Baseline Peak Dose p 
(mean _+ SD) (mean -+ SD) Value 
Heart rate (beats/min) 76 - 15 124 _+ 19 < 0.0001 
Systolic BP (mm Hg) 140 _+ 26 153 _+ 33 0.0001 
Diastolic BP (mm Hg) 75 _+ 14 69 + 17 0.003 
Rate-pressure product 10.7 _+ 3 19.9 _+ 5 < 0.0001 
(beats/min x mm Hg x 103) 
Ejection fraction (%) 53.5 _+ 16 63.9 + 13 < 0.0001 
There was a statistically significant increase in heart rate, systolic blood 
pressure (BP), rate-pressure product and ejection fraction and a decrease in 
diastolic blood pressure during dobutamine stress echocardiography. 
Left ventricular function was quantitated at baseline by 
echocardiographic analysis in the apical views according to the 
modified Simpson's rule. 
Coronary angiography. Coronary angiography was per- 
formed by the Judkins technique within 2 weeks of the 
dobutamine stress echocardiogram in 25 patients. Multiple 
angulated views of all coronary segments were obtained at 30 
frames/s with use of a Philips S-ray system. Visual estimates of 
coronary artery stenosis everity were determined by consensus 
agreement ofat least wo experienced angiographers who had 
no knowledge of the dobutamine echocardiographic results. 
Significant coronary artery disease was defined as a lumen 
narrowing of ->75%. 
Statistical analysis. Dichotomous variables were analyzed 
by the Fisher exact est. Continuous variables were examined 
using paired and unpaired Student  tests. A p value of 0.05 
defined statistical significance. 
Resu l ts  
Dobutamine stress echocardiography. Patients were as- 
signed to two groups according to dobutamine stress echocar- 
diographic results. Group I included patients with no ischemia 
(normal or infarcted myocardium, n = 69); group II included 
patients with an ischemic result (ischemia or mixed ischemia 
and infarct, n = 33). The maximal dose achieved was not 
significantly different between the two groups of patients. 
Atropine was administered in 22 patients (22%). Persistent 
adverse effects of chest pain and arrhythmia necessitated 
treatment with intravenous beta-blockers in two patients. 
Hemodynamic response to dobutamine infusion. Mean 
heart rate, rate-pressure product and ejection fraction in- 
creased significantly from baseline to peak dose in response to 
dobutamine infusion (Table 1). When the hemodynamic re- 
sponse to dobutamine was analyzed according to the dobut- 
amine stress echocardiographic results, there was no significant 
difference between patients who did or did not develop isch- 
emia (Table 2). A slight difference in these hemodynamic 
variables could not be excluded without studying many more 
patients. 
Mitral regurgitation. By color flow Doppler, no mitral 
regurgitation was present in 50 patients at baseline or at peak 
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Table 2. Hemodynamic Response by Dobutamine Stress 
Echocardiographic Result 
No Ischemia Ischemia p 
(mean + SD) (mean + SD) Value 
Change in heart rate (beats/rain) 47 + 20 49 _+ 21 0.7 
Change in SBP (mm Hg) 14 + 34 9 _+ 28 0.5 
Change in DBP (mm Hg) -4  _+ 19 -6  -+ 16 0.8 
Change in EF (%) 11 + 17 10 _+ 25 0.9 
Change in heart rate, systolic (SBP) and diastolic (DBP) blood pressure and 
ejection fraction (EF) from baseline to peak dobutamine infusion. 
Table 3. Effect on Mitral Regurgitation by Dobutamine Stress 
Echocardiographic Result 
Ischemia No Ischemia p Value 
No MR (n 50) 37 t3 0.01' 
No change in MR (n = 28) 15 13 0.84 
Decrease in MR (n - 22) 15 7 0.11 
Increase in MR (n = 2) 2 0 ¢ 
*Statistically significant. "~A p value calculation with n = 2 would be 
misleading. Data presented are numbers of patients in group. MR - mitral 
regurgitation. 
dobutamine infusion (Table 3). Of the 50 patients with base- 
line mitral regurgitation, the grade was unchanged in 28 
patients at peak dose (Fig. 1), whereas there was a decrease in
mitral regurgitation i 22 patients (Fig. 2). New mild mitral 
regurgitation developed in two patients only, both of whom 
had a normal dobutamine echocardiographic f ndings (Table 
3). Posterior or lateral ischemia developed in three patients 
with documented coronary artery disease, none of whom had 
worsening mitral regurgitation. Interobserver and intraob- 
server variability for assigning mitral regurgitation grade semi- 
quantitatively, by color flow Doppler, were 10% and 5%, 
respectively. Eccentric mitral regurgitation jets were seen in 5 
patients (5%). 
Mitral regurgitation and left ventricular function. Ejec- 
tion fraction at rest was quantitated in all but two of the 
patients with baseline or new mitral regurgitation during 
dobutamine stress echocardiography. Patients were assigned to 
two groups on the basis of rest left ventricular ejection fraction 
(ejection fraction <50% [mean 35 _+ 11%] and ->50% [mean 
63 _+ 9%)]). Blood pressure and heart rate responses to 
dobutamine infusion were not significantly different in pa- 
tients with a low rest ejection fraction compared with those 
with a normal ejection fraction (Fig. 3). However, during 
dobutamine infusion, there was a significantly greater increase 
in ejection fraction (mean 22 _+ 17%) in the group with a low 
rest ejection fraction than in the group with a high rest ejection 
fraction (mean 2 _+ 16%) (p < 0.0001). The maximal dobut- 
amine dose was not significantly different between these two 
groups. Although none of the patients with a rest ejection 
fraction <50% had worsening of mitral regurgitation, in two 
patients (7%) with a rest ejection fraction ->50%, mitral 
regurgitation worsened uring dobutamine stress echocardiog- 
raphy (Fig. 4) (p = 0.49). Twenty-three patients had an 
ejection fraction <50%, of whom 61% had improvement in 
mitral regurgitation (Fig. 4) with dobutamine infusion com- 
pared with 25% of 27 patients with a rest ejection fraction 
->50% (Fig. 4) (p = 0.02). 
Coronary angiography. Of 25 patients who underwent 
coronary angiography, 18 were found to have significant cor- 
onary artery disease. Of these 18 patients, 17 (94%) had 
ischemia, infarction or ischemia nd infarction during dobut- 
amine stress echocardiography. There were significant coro- 
nary lesions in 11 left anterior descending, 12 left circumflex 
and 9 right coronary artery territories. A decrease in ejection 
fraction was observed uring dobutamine infusion in 7 of the 
18 patients with significant coronary artery disease. Only 7 
(15%) of 47 patients with normal dobutamine stress echocar- 
diographic findings underwent coronary angiography, thus 
limiting assessment of the specificity of dobutamine stress 
echocardiography. 
Dobutamine stress electrocardiography. The ECG re- 
vealed significant ST segment depression during dobutamine 
infusion in 6% of patients with normal dobutamine echocar- 
diographic results compared with 21% of patients with isch- 
emic results. Twenty-seven percent of patients with echocar- 
diographic infarction also had positive ECG findings. 
Discuss ion  
A previous tudy by Mazeika et al. (3) suggested that the 
development of new mitral regurgitation during dobutamine 
stress echocardiography improves the sensitivity of this test for 
detecting coronary artery disease from 78% to 81% without a 
decrease in specificity (3). However, studies to date have an 
insufficient number of patients with coronary angiographic 
data to make definitive conclusions about the effect of new 
mitral regurgitation on the sensitivity and specificity of dobut- 
amine stress echocardiography. Therefore, it was not the 
purpose of this study to answer this question; rather, we wished 
to examine the effect of dobutamine stress echocardiography 
on mitral regurgitation. The major finding in the current study 
was that dobutamine stress echocardiography induces new or 
worsening mitral regurgitation i  very few patients. Further- 
more, no patient who developed wall motion abnormalities 
consistent with ischemia exhibited new or worsening mitral 
regurgitation. 
Mechanisms of mitral regurgitation. This study confirms 
the beneficial effect of dobutamine on mitral regurgitation i  
patients with left ventricular dysfunction. The mechanism of 
this beneficial effect remains unclear, although it may be 
related to a decrease in afterload or mitral orifice size that 
results from the vasodilatory and inotropic effects of dobut- 
amine (8). Kaul et al. (12) reported that incomplete mitral 
leaflet closure led to ischemic mitral regurgitation even with- 
out regional dyskinesia but with global eft ventricular dysfunc- 
tion. The latter mechanism ay explain the benefit of the 
inotropic effect of dobutamine on mitral regurgitation i  
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Figure 1. No change in mitral regurgitation 
grade from baseline to peak stress was observed 
despite development of anterior and anterosep- 
tal ischemia during dobutamine stress echocar- 
diography. 
patients with left ventricular dysfunction with or without 
ischemia. 
Study limitations. Most of the patients in this study did not 
undergo coronary angiography. Therefore no reference stan- 
dard was available to assess coronary artery disease status. 
However, the high sensitivity and specificity of dobutamine 
stress echocardiography for detecting coronary artery disease 
has been well documented (1-4). Previous studies (10,13,14) 
have shown good correlation between mitral regurgitation 
color jet area and the angiographic grade of mitral regurgita- 
tion. However, the color flow jet area does not correlate well 
with angiographic estimates of regurgitant fraction or volume 
(10,13), which is not surprising because color flow Doppler 
areas do not take spatial or temporal variability into account. 
Furthermore, it is generally assumed that the larger the jet 
area, the greater the severity of mitral regurgitation. However, 
technical and anatomic factors may influence the color jet area. 
It has been demonstrated that gain settings, pulse repetition 
frequency, transducer f equency, scanning depth, and filter 
settings can all influence the color Doppler jet area (15-18). 
We attempted tominimize this potential source of variability 
by optimizing these technical factors during the baseline 
examination a d maintaining these settings on the same ultra- 
sound machine for the peak dobutamine dose image. In this 
study, interobserver variability in assessing the grade of mitral 
regurgitation by color flow Doppler areas was well within 
Figure 2. Mitral regurgitation grade im- 
proved from moderate omild in this patient 
with a rest left ventricular ejection fraction 
<50%. 
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Figure 3. Hemodynamic effects of dobutamine on left ventricular 
function. No significant difference (A) was observed in heart rate (HR) 
or systolic (SBP) or diastolic (DBP) blood pressure response to 
dobutamine infusion in patients with an ejection fraction (EF) < 50% 
versus those with an ejection fraction ->50%. 
previously reported ranges (19,20). The color Doppler jet area 
of eccentric mitral regurgitation may underestimate he regur- 
gitant volume because the impingement of the jet on the atrial 
wall results in decreased momentum (21,22). In this study only 
five patients had eccentric mitral regurgitation jets. As with 
other studies of color flow Doppler estimates of mitral regur- 
gitation, the present study also lacks a reliable reference 
standard method for comparison. Contrast ventriculography 
also has technical imitations with regard to evaluating mitral 
regurgitation (23,24). The present study is a preliminary anal- 
ysis of the effect of dobutamine stress echocardiography on 
mitral regurgitation. Future studies on this topic should be 
performed with quantitative Doppler methods and include 
larger numbers of patients with coronary angiographic data. 
Conclusions. It has been previously suggested (25) that 
detection of ischemic mitral regurgitation has important prog- 
nostic implications that affect management decisions. How- 
ever, on the basis of the results of this study, dobutamine stress 
echocardiography does not identify patients with ischemic 
mitral regurgitation. In fact, very few patients develop new or 
worsening mitral regurgitation during dobutamine infusion 
k l  "w 
"['MR No A MR SMR 
Figure 4. Effects of dobutamine on mitral regurgitation (MR) and left 
ventricular function. Mitral regurgitation grade did not change (No A) 
or worsen (upward arrow) significantly in patients with a rest left 
ventricular ejection fraction <50% or ->50%. However, significantly 
more patients with an ejection fraction <50% had improvement 
(downward arrow) in mitral regurgitation than those with a normal 
ejection fraction. 
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even with development of new or worsening wall motion 
abnormalities that are consistent with an ischemic response. 
To the contrary, this study demonstrated that many patients 
have an improvement in mitral regurgitation during dobut- 
amine stress echocardiography, particularly those with preex- 
isting left ventricular dysfunction. Future studies with larger 
numbers of patients would be necessary to assess the effect of 
mitral regurgitation on the sensitivity and specificity of dobut- 
amine echocardiography. 
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